144 related articles for article (PubMed ID: 10769584)
1. [Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].
Scheen AJ
Rev Med Liege; 2000 Feb; 55(2):121-4. PubMed ID: 10769584
[TBL] [Abstract][Full Text] [Related]
2. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
3. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
[TBL] [Abstract][Full Text] [Related]
4. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
5. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.
Hoogwerf BJ; Young JB
Cleve Clin J Med; 2000 Apr; 67(4):287-93. PubMed ID: 10780101
[TBL] [Abstract][Full Text] [Related]
6. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E does not prevent cardiovascular events in high-risk patients.
Flynn T; Stevermer JJ
J Fam Pract; 2000 Apr; 49(4):372-3. PubMed ID: 10778845
[No Abstract] [Full Text] [Related]
8. [Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].
Scheen AJ
Rev Med Liege; 1999 Oct; 54(10):835-6. PubMed ID: 10605322
[TBL] [Abstract][Full Text] [Related]
9. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
Mancini GB; Stewart DJ
Can J Cardiol; 2001 May; 17 Suppl A():15A-7A. PubMed ID: 11381289
[TBL] [Abstract][Full Text] [Related]
10. Modifying the natural history of atherosclerosis: the SECURE trial.
Lonn E
Int J Clin Pract Suppl; 2001 Jan; (117):13-8. PubMed ID: 11715353
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on ramipril in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
[TBL] [Abstract][Full Text] [Related]
12. The ADVANCE trial.
Procopiou M
Lancet; 2008 Jan; 371(9606):25; author reply 26. PubMed ID: 18177767
[No Abstract] [Full Text] [Related]
13. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Böhm M; Baumhäkel M; Mahfoud F; Werner C
Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
[TBL] [Abstract][Full Text] [Related]
14. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
Gerstein HC; Bosch J; Pogue J; Taylor DW; Zinman B; Yusuf S
Diabetes Care; 1996 Nov; 19(11):1225-8. PubMed ID: 8908384
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
[TBL] [Abstract][Full Text] [Related]
17. Blood-pressure reduction and cardiovascular risk in HOPE study.
Sleight P; Yusuf S; Pogue J; Tsuyuki R; Diaz R; Probstfield J;
Lancet; 2001 Dec 22-29; 358(9299):2130-1. PubMed ID: 11784631
[TBL] [Abstract][Full Text] [Related]
18. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
Pocanić D
Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282
[TBL] [Abstract][Full Text] [Related]
19. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario.
Tu K; Mamdani MM; Jacka RM; Forde NJ; Rothwell DM; Tu JV
CMAJ; 2003 Mar; 168(5):553-7. PubMed ID: 12615747
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular protection: a breakthrough for high-risk patients?
Ferrari R
J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
